Context Therapeutics Inc.

NASDAQ: CNTX · Healthcare · Biotechnology

PublicHQ Philadelphia, PA · PhiladelphiaCIK 0001842952Reports USD

#1 of 1,418 Healthcare companies by revenue

EA Score

——

FH 54DQ —GM —SS 35

v0.1 · 35/100 weight · pillars only

↑ balance-sheet leverage, filing timeliness · ↓ listing tenure, Piotroski F

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$36.1M

Employees

as of 2026-08-19

Market cap

$45.6M

as of 2026-08-19

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$36.1M-$36.1M2025

Operating income-$39.7M-$39.7M2025

Total assets$68.5M$68.5M2025

Liabilities$8.0M$8.0M2025

Equity$60.5M$60.5M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Context Therapeutics Inc.’s financial profile?

Context Therapeutics Inc. earned -$36.1M in FY2025 net income.

Peers · Healthcare

Apollomics, Inc.——Mach7 Technologies Limited——Vicapsys Life Sciences, Inc.——Cell Source, Inc.——Rocket Doctor AI Inc.——BetterLife Pharma Inc.——

Neighbors

Philadelphia →

Comcast Corporation$123.7B86A Carpenter Technology Corporation$2.9B84B+Aramark$18.5B64C Five Below, Inc.$4.8B74B Axalta Coating Systems Ltd.$5.1B77B+Urban Outfitters, Inc.$6.2B73B

Key facts

CEOMartin A. Lehr

SectorHealthcare

IndustryBiotechnology

HeadquartersPhiladelphia, PA

ExchangeNASDAQ: CNTX

Employees15

IPO date2021-10-20

Latest filings

8-K2026-08-05 10-Q2026-08-05 8-K2026-07-31 8-K2026-06-26 8-K2026-06-15 8-K2026-05-18 10-Q2026-05-06 8-K2026-05-01

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.